National Health Investors, Inc.

National Health Investors, Inc. Earnings Recaps

NHI Real Estate 2 recaps
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Nov 13, 2026

NHI shares fell 4.8% after the company said third-quarter SHOP performance fell short of expectations: weaker-than-expected contributions from non-same-store communities offset 19.5% year-over-year NOI growth at same-store properties. Management said it is addressing operating performance with partners, but the shortfall puts execution of its SHOP growth strategy in focus.

Key takeaways
  • The 15 same-store SHOP properties delivered approximately 19.5% year-over-year NOI growth, in line with NHI’s outlook; non-same-store communities contributed less than expected.
  • NHI completed $396.2 million of investments year-to-date at an average 7.5% yield, including $320 million of SHOP investments at a 7.3% average year-one yield after routine CapEx.
  • The company expects about $190 million of signed-LOI investments to close in the fourth quarter, bringing projected 2026 investment to approximately $590 million. Expected year-end acquisitions will initially be net leased, with anticipated SHOP conversions in 2027.
  • SHOP’s share of total NOI rose to approximately 18%, from 9% entering the year, including an October acquisition. Management reiterated its target of high-single-digit to low-double-digit organic SHOP NOI growth.
  • NHI said leverage is below 3x and expects to recycle more than 95% of the NHC sale proceeds before year-end; the sale generated $555 million in net proceeds.
Q3 2025 Nov 9, 2025

National Health Investors reported a robust third quarter with a notable 63% increase in SHOP NOI, bolstered by strategic property transitions and a strong acquisition pipeline, leading to a third upward revision in annual guidance.

Key takeaways
  • SHOP NOI growth of approximately 63% year-over-year, driven by the transition of 7 properties.
  • First SHOP acquisition completed for $74.3 million, expected to yield an NOI of 8.2%.
  • Full-year guidance raised for a projected NFFO per share growth of over 10%, marking the strongest growth since 2014.
  • A solid pipeline of acquisitions valued at $195 million under signed Letters of Intent, anticipated to close in late 2025 and early 2026.
  • Financial health remains strong with a net debt to adjusted EBITDA of 3.6x and over $1 billion in available liquidity, providing a competitive advantage.